BioCentury
ARTICLE | Finance

Many happy returns

Totting up investor returns on Receptos following Celgene's acquisition offer

July 20, 2015 7:00 AM UTC

A postmortem on Receptos Inc. (NASDAQ:RCPT) shows participants in each and every financing event for the company have seen their investments at least double, and in some cases increase by an order of magnitude.

Even before Celgene Corp. (NASDAQ:CELG) announced plans to buy the immune and metabolic disease company for $232 per share, or $7.2 billion net of cash, the returns for Receptos' founding VCs were stellar. ...